BioPharma Dive5d
First Prader-Willi drug to reduce hunger approved by FDA
Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.
MedCity News4d
Rare Metabolic Disease That Leads to Childhood Obesity Gets Its First FDA-Approved Drug
This rare disease, Prader-Willi syndrome, has been described in medical literature for nearly 70 years. But even as medical understanding of the disorder grew, efforts to develop a drug to treat i ...
Disability Scoop3d
FDA Green-Lights First Treatment For Prader-Willi Syndrome
The Food and Drug Administration approved a medication this week known as VYKAT XR to treat hyperphagia — or an incessant feeling of hunger — in kids and adults with Prader-Willi syndrome. The ...
Monthly Prescribing Reference3d
Vykat XR Approved to Treat Hyperphagia in Prader-Willi Syndrome
Though the exact mechanism of action is unclear, it is believed that in patients with Prader-Willi syndrome, diazoxide choline reduces hyperphagia through activation of the adenosine triphosphate ...
MedPage Today4d
FDA OKs First Drug for Hyperphagia in Prader-Willi Syndrome
"The FDA approval of Vykat XR is an incredible achievement for the entire PWS [Prader-Willi syndrome] community. I am excited to have Vykat XR available to help treat hyperphagia, which is the ...
Reuters5d
US FDA approves first treatment for rare genetic disorder Prader-Willi syndrome
The drug, to be called Vykat XR, treats hyperphagia, the hallmark symptom of the Prader-Willi syndrome, a genetic disorder caused by full or partial deletions on chromosome 15 that affect the ...
Healio4d
FDA approves first therapy to treat hyperphagia in Prader-Willi syndrome
Diazoxide choline extended-release is the first FDA-approved therapy to address hyperphagia in Prader-Willi syndrome. Soleno Therapeutics announced the medication will be available beginning in April.